Panoptes Pharma Ges.m.b.H.

Founded

2013

Staff

Organization type

RDM biotech/pharma

Region

Vienna

Panoptes Pharma is a clinical stage company developing small molecule drugs for eye diseases, in particular for autoimmune uveitis, dry eye disease and adenoviral conjunctivitis. Our lead program, PaniJect, is currently in an open label phase 1b/2a study in patients with non infectious uveitis, followed by our ocular surface program, PaniDrop (combining a proprietary delivery technology with an NCE) which is phase 1/2 ready for the indication dry eye disease.